551-09-7

Upstream product

• 157-17-5 azirene 
• 134-32-7 1-amino-naphthalene 
• 1465-25-4 N-(1-naphthyl)ethylenediamine dihydrochloride 
• 6580-20-7 methyl 3-(naphthalen-1-ylamino)propanoate 
• 1211429-34-3 C₁₃H₁₅N₃O 
• 870-24-6 2-chloroethanamine hydrochloride 
• 107-15-3 ethylenediamine 
• 86-48-6 1-hydroxy-2-naphthoic acid 
• 90-11-9 1-Bromonaphthalene 
• 90-15-3 α-naphthol 

Downstream Products

• 13231-94-2 4-[4-(2-Amino-ethylamino)-naphthalen-1-ylazo]-benzenesulfonamide 
• 1027725-24-1 N-[2-(3,4-dimethoxyphenyl)ethyl]-N'-(1-naphthyl)ethane-1,2-diamine 
• 1027898-33-4 N-[2-(4-methoxyphenyl)ethyl]-N'-(1-naphthyl)ethane-1,2-diamine 

Relevant academic research and scientific papers

Cystine cholesterol gel factor and preparation method thereof

The cystine cholesterol gel factor is obtained by taking natural product cholesterol and cystine as a raw material and carrying out chemical reaction. The invention also discloses a supramolecular gel which is prepared from the gel factors in benzene solvents. The micro-morphology is a regular nanobelt or nano fiber network structure in a solvent such as n-propanol or cyclohexane. Raw materials used in the preparation process of the gel factor and the supramolecular gel belong to natural small molecule compounds, and have the advantages of wide sources, good biocompatibility, unique structure and the like, and exhibit better ion selective recognition and reduction response characteristics. The gel system has good biocompatibility and environmental friendliness, provides a new idea for construction of the intelligent response gel material, and provides a new reference for expanding the application of the cystine and the cholesterol natural small molecule compound in the supermolecule field.

Synthesis and characterization of N-substitutional ethylenediamine derivatives

N-Substituted and N,N-disubstituted ethylenediamine derivatives were prepared rapidly in aqueous conditions from 30 to 76 % yields, respectively, on a multi-gram scale starting from inexpensive and commercially available starting materials. The steps involved Michael addition, hydrazinolysis and Curtius rearrangements. The highlight of this method lies on its convenience and economy in accessing these intermediates.

Synthesis of short and long-wavelength functionalised probes: amino acids' labelling and photophysical studies

Fluorescent labelling of α-amino acids at their N or C terminals in the main and lateral chains at short and long wavelengths was carried out in different ways. The N-[3-(naphthalen-1-ylamino)propanoyl]amino acid methyl esters synthesised showed strong fluorescence in the visible region (～415 nm) of the electromagnetic spectrum. Condensation of these compounds with 5-diethylamino-2-nitrosophenol or 5-ethylamino-4-methyl-2-nitrosophenol produced the benzo[a]phenoxazine derivatives, with maximum emission wavelengths shifted to values higher than 644 nm. The synthesis of novel functionalised 5,9-diaminobenzo[a]phenoxazinium salts, by reaction of 5-ethylamino-4-methyl-2-nitrosophenol and N-substituted 1-naphthylamine and their use in the covalent labelling of the N or C terminals of valine, produced derivatives with long-wavelength emissions (644-653 nm). Photophysical studies using the synthesised compounds both in different solvents and in controlled pH were undertaken. Preliminary evaluation of photostability of the cationic polycyclic heterocycles in ethanol and water at physiological pH was also performed.

ANTIPARASITIC TERPENE ALKALOIDS

The present invention relates to novel terpene alkaloids and their use as antiparasitic agents. The present invention also relates to an antiparasitic agent which comprises a terpene alkaloid compound of this invention as an effective ingredient in an antiparasitic formulation. More particularly, the present invention relates to derivatives of the terpene alkaloid (1S,2R,4aS,5R,8R,8aR)-2-(acetyloxy)-8a-hydroxy-3,8-dimethyl-5-(1-methylethenyl)-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl (2S,3aR,9bR)-6-chloro-9b-hydroxy-5-methyl-1,2,3,3a,5,9b-hexahydropyrrolo[2,3-c][2,1]benzoxazine-2-carboxylate. Pharmaceutical compositions comprising the same are also disclosed.

Chelating compounds and their use

A chelating compound of the formula: wherein R is an aromatic ring-containing organic group, A is a residue of an aminopolyacetic acid excluding acetic acid groups (--CH2 COOH) therefrom, m is an integer of at least two and n is an integer of 1 or 2, or its salt, which has a specificity to a hepatobiliary system so that a complex formed between said chelating compound and a metallic element through a coordinate bond is useful and a diagnostic or therapeutic agent for hepatobiliary organs and tissues.

S-NITROSOCAPTOPRIL COMPOUNDS AND THE USE THEREOF

The invention relates to novel nitroso compounds having the formula: STR1 wherein, R is hydroxy, NH 2, NHR 4, NR 4 R. sup.5 or C 1-C 7 alkoxy, wherein R 4 and R 5 are C 1-C 4 alkyl, aryl, or C 1-C 4 alkyl substituted by aryl;R 1 is hydrogen, C 1-C 7 alkyl or C 1-C. sub.7 alkyl substituted by phenyl, amino, guanidino, NHR 6 or NR 6 R. sup.7, wherein R 6 and R 7 are methyl, or C 1-C 4 acyl; R 3 is hydrogen, C 1-C 7 alkyl or C. sub.1-C 7 alkyl substituted by phenyl;n is 0 to 2; P>A is hydrogen,lower C 1-C 7 alkyl,lower C 2-C 7 alkylene, lower C 2-C 7 alkylene substituted by hydroxy, C 1-C 4 alkyl, aryl, orP>a C 4-C 7 ring which may be fused to a benzene ring;B is hyrogen, lower C. sub.1-C 7 alkyl,phenyl, lower C 1-C 7 substituted by phenyl, hydroxy, guanidino, amino, imidazoyl, indolyl, mercapto, mercapto substituted by lower C 1-C. sub.4 alkyl, carbamoyl, or carboxyl, orlower C 2-C. sub.7 alkylene.The invention also relates to compounds having the following formula: STR2 wherein R, R 1, R 3 and n are as defined above; R 2 is hydrogen, hydroxy, C 1-C 4 alkoxy, aryloxy or C 1-C 7 alkyl; and m is 1 to 3.The invention also relates to pharmaceutical compositions comprising the nitrosothiol compounds of the invention together with a pharmaceutically acceptable carrier.The invention also relates to methods for treating acute myocardial infarction, left ventricular dysfunction without overt heat failure, hypertension, pulmonary hypertension, congestive heart failure, angina pectoris, vascular thrombosis, Raynauds syndrome, Scleroderma, toxemia of pregnancy, acute renal failure, diabetic nephropathy, and renal artery stenosis, and to methods of inhibiting ACE and effecting vasodilation comprising administering the nitrosothiol compounds of the invention to an animal.